Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nat Struct Mol Biol. 2022 Jul;29(7):677-687. doi: 10.1038/s41594-022-00796-6. Epub 2022 Jul 14.
Serotonin receptors are important targets for established therapeutics and drug development as they are expressed throughout the human body and play key roles in cell signaling. There are 12 serotonergic G protein-coupled receptor members encoded in the human genome, of which the 5-hydroxytryptamine (5-HT) receptor (5-HTR) is the least understood and lacks selective tool compounds. Here, we report four high-resolution (2.73-2.80 Å) structures of human 5-HTRs, including an inactive state structure bound to an antagonist AS2674723 by crystallization and active state structures bound to a partial agonist lisuride and two full agonists, 5-carboxamidotryptamine (5-CT) and methylergometrine, by cryo-EM. Leveraging the new structures, we developed a highly selective and potent antagonist for 5-HTR. Collectively, these findings both enhance our understanding of this enigmatic receptor and provide a roadmap for structure-based drug discovery for 5-HTR.
血清素受体是既定治疗方法和药物开发的重要靶点,因为它们在人体全身表达,并在细胞信号转导中发挥关键作用。人类基因组中编码了 12 个血清素能 G 蛋白偶联受体成员,其中 5-羟色胺(5-HT)受体(5-HTR)了解最少,缺乏选择性工具化合物。在这里,我们报告了四个高分辨率(2.73-2.80Å)的人类 5-HTR 结构,包括通过结晶与拮抗剂 AS2674723 结合的非活性状态结构,以及通过 cryo-EM 与部分激动剂利舒肽和两种完全激动剂 5-羧基色胺(5-CT)和甲基麦角新碱结合的活性状态结构。利用新结构,我们开发了一种对 5-HTR 具有高选择性和高活性的拮抗剂。总的来说,这些发现既增强了我们对这个神秘受体的理解,也为基于结构的 5-HTR 药物发现提供了路线图。